| Oaks At Northpointe | |
| 3291 Northpointe Drive, Zanesville, Ohio 43701 | |
| (740) 452-3000 | |
| Name | Oaks At Northpointe |
|---|---|
| Location | 3291 Northpointe Drive, Zanesville, Ohio |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 75 |
| Occupancy Rate | 81.6% |
| Medicare ID (CCN) | 366051 |
| Legal Business Name | Trilogy Healthcare Of Muskingum Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1609181700 |
| Organization Name | TRILOGY HEALTHCARE OF MUSKINGUM, LLC |
| Doing Business As | THE OAKS AT NORTHPOINTE |
| Address | 3291 Northpointe Drive, Zanesville, OH 43701 |
| Phone Number | 740-452-3000 |
News Archive
A recent study published in the July 2015 issue of the Journal of the American Academy of Child and Adolescent Psychiatry demonstrates that early intervention, beginning between 18 and 30 months of age improves outcomes for children with autism spectrum disorder (ASD) at age 6.
Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.
An international panel of leading scientists is launching a new TripAdvisor-style website aimed at helping researchers choose better-quality research tools - and avoiding potentially serious errors in biomedical research.
A new executive briefing sponsored by Systematic Development Group brings to light the top seven methods that healthcare organizations should apply to reduce the effects of a data breach and minimize data breach insurance costs. Some hospitals may be surprised to find that although they have a data breach insurance policy in place, several of the biggest threats of a data breach may not be covered under the plan.
Verenium Corporation a pioneer in the development and commercialization of high-performance enzyme solutions, today announced that it has renewed and extended its joint marketing agreement with Alfa Laval, a leading global provider of heat transfer, separation and fluid handling technologies, for Purifine PLC.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A recent study published in the July 2015 issue of the Journal of the American Academy of Child and Adolescent Psychiatry demonstrates that early intervention, beginning between 18 and 30 months of age improves outcomes for children with autism spectrum disorder (ASD) at age 6.
Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.
An international panel of leading scientists is launching a new TripAdvisor-style website aimed at helping researchers choose better-quality research tools - and avoiding potentially serious errors in biomedical research.
A new executive briefing sponsored by Systematic Development Group brings to light the top seven methods that healthcare organizations should apply to reduce the effects of a data breach and minimize data breach insurance costs. Some hospitals may be surprised to find that although they have a data breach insurance policy in place, several of the biggest threats of a data breach may not be covered under the plan.
Verenium Corporation a pioneer in the development and commercialization of high-performance enzyme solutions, today announced that it has renewed and extended its joint marketing agreement with Alfa Laval, a leading global provider of heat transfer, separation and fluid handling technologies, for Purifine PLC.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 3 |
| Total Amount of Fines in Dollars | $29555 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 3 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 17.11 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.23 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 65.79 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.52 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.48 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 15.02 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 9.28 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.16 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.38 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 91.84 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.81 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 34.42 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 34.17 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 1.69 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.85 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 82.51 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 92.74 | 82.93 |
News Archive
A recent study published in the July 2015 issue of the Journal of the American Academy of Child and Adolescent Psychiatry demonstrates that early intervention, beginning between 18 and 30 months of age improves outcomes for children with autism spectrum disorder (ASD) at age 6.
Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.
An international panel of leading scientists is launching a new TripAdvisor-style website aimed at helping researchers choose better-quality research tools - and avoiding potentially serious errors in biomedical research.
A new executive briefing sponsored by Systematic Development Group brings to light the top seven methods that healthcare organizations should apply to reduce the effects of a data breach and minimize data breach insurance costs. Some hospitals may be surprised to find that although they have a data breach insurance policy in place, several of the biggest threats of a data breach may not be covered under the plan.
Verenium Corporation a pioneer in the development and commercialization of high-performance enzyme solutions, today announced that it has renewed and extended its joint marketing agreement with Alfa Laval, a leading global provider of heat transfer, separation and fluid handling technologies, for Purifine PLC.
› Verified 2 days ago
Continuing Healthcare At Adams Lane Location: 1856 Adams Lane, Zanesville, Ohio 43701 Phone: (740) 454-9769 | |
Continuing Healthcare At Willow Haven Location: 1020 Taylor Street, Zanesville, Ohio 43701 Phone: (740) 454-9747 | |
Continuing Healthcare At Cedar Hill Location: 1136 Adair Avenue, Zanesville, Ohio 43701 Phone: (740) 454-6823 | |
Continuing Healthcare At Sterling Suites Location: 1126 Adair Avenue, Zanesville, Ohio 43701 Phone: (740) 452-2087 | |